![]() ![]() | Turner, M. C., Radzikowska, U., Ferastraoaru, D. E., Pascal, M., Wesseling, P., McCraw, A., BACKES, C., Bax, H. J., Bergmann, C., Bianchini, R., Cari, L., de Las Vecillas, L., Izquierdo, E., Lind-Holm Mogensen, F., MICHELUCCI, A., NAZAROV, P., NICLOU, S. P., Nocentini, G., OLLERT, M., ... Poli, A. (2024). AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper. Allergy. doi:10.1111/all.15994 ![]() |
![]() ![]() | Oudin, A., Moreno-Sanchez, P. M., Baus, V., NICLOU, S. P., & GOLEBIEWSKA, A. (02 January 2024). Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence. BMC Cancer, 24 (1), 3. doi:10.1186/s12885-023-11774-6 ![]() |
![]() ![]() | Nassiri, F., Aldape, K., Alhuwalia, M., Brastianos, P., Ducray, F., Galldiks, N., Kim, A., Lamszus, K., Mitchell, D., Nabors, L. B., Nam, D.-H., Natsume, A., Ng, H.-K., NICLOU, S. P., Sahm, F., Short, S., Walsh, K., Wick, W., & Zadeh, G. (2024). Highlights of the inaugural ten - the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 1 (1), 016. doi:10.1093/noajnl/vdz016 ![]() |
![]() ![]() | Nesseler, J. P., Schaue, D., McBride, W. H., Lee, M.-H., Kaprealian, T., NICLOU, S. P., & Nickers, P. (2024). Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. Advances in Radiation Oncology, 4 (2), 268-282. doi:10.1016/j.adro.2018.11.005 ![]() |
![]() ![]() | Cano-Galiano, A., Oudin, A., Fack, F., Allega, M.-F., Sumpton, D., Martinez-Garcia, E., DITTMAR, G., Hau, A.-C., De Falco, A., Herold-Mende, C., Bjerkvig, R., MEISER, J., Tardito, S., & NICLOU, S. P. (2024). Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas. Neuro-Oncology Advances, 3 (1), 057. doi:10.1093/noajnl/vdab057 ![]() |
![]() ![]() | Erasimus, H., GOBIN, M., NICLOU, S. P., & Van Dyck, E. (2024). DNA repair mechanisms and their clinical impact in glioblastoma. Mutation Research - Reviews in Mutation Research, 769, 19-35. doi:10.1016/j.mrrev.2016.05.005 ![]() |
NICLOU, S. P., Ehlert, E. M. E., & Verhaagen, J. (2024). Chemorepellent axon guidance molecules in spinal cord injury. Journal of Neurotrauma, 23 (3-4), 409-21. doi:10.1089/neu.2006.23.409 ![]() |
![]() ![]() | Neirinckx, V., Hau, A.-C., Schuster, A., FRITAH, S., Tiemann, K., KLEIN, E., NAZAROV, P., Matagne, A., SZPAKOWSKA, M., MEYRATH, M. M. R., Chevigné, A., Schmidt, M. H. H., & NICLOU, S. P. (2024). The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma. Neuro-Oncology Advances, 1 (1), 024. doi:10.1093/noajnl/vdz024 ![]() |
![]() ![]() | Malta, T. M., Sabedot, T. S., Morosini, N. S., Datta, I., Garofano, L., Vallentgoed, W. R., Varn, F. S., Aldape, K., D'Angelo, F., Bakas, S., Barnholtz-Sloan, J. S., Gan, H. K., Hasanain, M., Hau, A.-C., Johnson, K. C., Cazacu, S., deCarvalho, A. C., Khasraw, M., Kocakavuk, E., ... Noushmehr, H. (2023). The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen. Cancer Research. doi:10.1158/0008-5472.CAN-23-2093 ![]() |
Yabo, Y. A., Moreno-Sanchez, P. M., Pires-Afonso, Y., Kaoma, T., Nosirov, B., Scafidi, A., Ermini, L., Lipsa, A., Oudin, A., KYRIAKIS, D., GRZYB, K., POOVATHINGAL, S. K., Poli, A., Muller, A., TOTH, R., KLINK, B., BERCHEM, G. J. M. J., Berthold, C., HERTEL, F., ... GOLEBIEWSKA, A. (2023). Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/60199. doi:10.1101/2023.03.05.531162 |
![]() ![]() | Le Rhun, E., Boele, F., Minniti, G., Galldiks, N., Taphoorn, M., Piil, K., Rudà, R., NICLOU, S. P., Geurts, M., Preusser, M., Weller, M., Short, S. C., & Dirven, L. (2023). Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiative. Neuro-Oncology Practice. doi:10.1093/nop/npad064 ![]() |
![]() ![]() | Biswas, A., Salvucci, M., Connor, K., Düssmann, H., Carberry, S., Fichtner, M., King, E., Murphy, B., O'Farrell, A. C., Cryan, J., Beausang, A., Heffernan, J., Cremona, M., Hennessy, B. T., Clerkin, J., Sweeney, K. J., MacNally, S., Brett, F., O'Halloran, P., ... Prehn, J. H. M. (June 2023). Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors. Journal of Neuro-Oncology, 163 (2), 327-338. doi:10.1007/s11060-023-04341-3 ![]() |
![]() ![]() | Capper, D., Reifenberger, G., French, P. J., Schweizer, L., Weller, M., Touat, M., NICLOU, S. P., Euskirchen, P., Haberler, C., Hegi, M. E., Brandner, S., Le Rhun, E., Rudà, R., Sanson, M., Tabatabai, G., Sahm, F., Wen, P. Y., Wesseling, P., Preusser, M., & van den Bent, M. J. (04 May 2023). EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology, 25 (5), 813-826. doi:10.1093/neuonc/noad008 ![]() |
![]() ![]() | Poli, A., Oudin, A., Muller, A., Salvato, I., Scafidi, A., Hunewald, O., Domingues, O., NAZAROV, P., Puard, V., Baus, V., AZUAJE, F., DITTMAR, G., ZIMMER, J., MICHEL, T., MICHELUCCI, A., NICLOU, S. P., & OLLERT, M. (March 2023). Allergic airway inflammation delays glioblastoma progression and reinvigorates systemic and local immunity in mice. Allergy, 78 (3), 682-696. doi:10.1111/all.15545 ![]() |
![]() ![]() | NICLOU, S. P., & GOLEBIEWSKA, A. (February 2023). How to move a “fried egg”: membrane blebbing in oligodendrogliomas. Neuro-Oncology, 25 (6), 1044–1046. doi:10.1093/neuonc/noad039 ![]() |
![]() ![]() | Pati, S., Baid, U., Edwards, B., Sheller, M., Wang, S.-H., Reina, G. A., Foley, P., Gruzdev, A., Karkada, D., Davatzikos, C., Sako, C., Ghodasara, S., Bilello, M., Mohan, S., Vollmuth, P., Brugnara, G., Preetha, C. J., Sahm, F., Maier-Hein, K., ... Bakas, S. (26 January 2023). Author Correction: Federated learning enables big data for rare cancer boundary detection. Nature Communications, 14 (1), 436. doi:10.1038/s41467-023-36188-7 ![]() |
Dosquet, H., Neirinckx, V., MEYRATH, M. M. R., Wantz, M., HAAN, S., NICLOU, S. P., SZPAKOWSKA, M., & Chevigné, A. (2023). Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). In Chapter One - Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). Elsevier. doi:10.1016/bs.mie.2022.09.002 ![]() |
![]() ![]() | Pati, S., Baid, U., Edwards, B., Sheller, M., Wang, S.-H., Reina, G. A., Foley, P., Gruzdev, A., Karkada, D., Davatzikos, C., Sako, C., Ghodasara, S., Bilello, M., Mohan, S., Vollmuth, P., Brugnara, G., Preetha, C. J., Sahm, F., Maier-Hein, K., ... Bakas, S. (05 December 2022). Federated learning enables big data for rare cancer boundary detection. Nature Communications, 13 (1), 7346. doi:10.1038/s41467-022-33407-5 ![]() |
![]() ![]() | Pires-Afonso, Y., Muller, A., GRZYB, K., Oudin, A., Yabo, Y. A., SOUSA, C., Scafidi, A., Poli, A., COSMA, A., HALDER, R., COOWAR, D., GOLEBIEWSKA, A., SKUPIN, A., NICLOU, S. P., & MICHELUCCI, A. (September 2022). Elucidating tumour-associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency. Molecular Oncology, 16 (17), 3167 - 3191. doi:10.1002/1878-0261.13287 ![]() |
![]() ![]() | Venkataramani, V., Yang, Y., Schubert, M. C., Reyhan, E., Tetzlaff, S. K., Wißmann, N., Botz, M., Soyka, S. J., Beretta, C. A., Pramatarov, R. L., Fankhauser, L., Garofano, L., Freudenberg, A., Wagner, J., Tanev, D. I., Ratliff, M., Xie, R., Kessler, T., Hoffmann, D. C., ... Winkler, F. (04 August 2022). Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell, 185 (16), 2899-2917.e31. doi:10.1016/j.cell.2022.06.054 ![]() |
![]() ![]() | ILINA, E., CIALINI, C., GERLOFF, D., Duarte Garcia-Escudero, M., Jeanty, C., Thézénas, M.-L., Lesur, A., Puard, V., Bernardin, F., Moter, A., Schuster, A., Dieterle, M., GOLEBIEWSKA, A., GERARDY, J.-J., DITTMAR, G., NICLOU, S. P., Müller, T., & MITTELBRONN, M. (18 February 2022). Enzymatic activity of glycosyltransferase GLT8D1 promotes human glioblastoma cell migration. iScience, 25 (2), 103842. doi:10.1016/j.isci.2022.103842 ![]() |
![]() ![]() | KISHK, A., PIRES PACHECO, M. I., HEURTAUX, T., SINKKONEN, L., PANG, J., Fritah, S., NICLOU, S., & SAUTER, T. (2022). Review of Current Human Genome-Scale Metabolic Models for Brain Cancer and Neurodegenerative Diseases. Cells, 11 (16). doi:10.3390/cells11162486 ![]() |
![]() ![]() | Yabo, Y. A., NICLOU, S. P., & GOLEBIEWSKA, A. (December 2021). Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro-Oncology, 24 (5), 669–682. doi:10.1093/neuonc/noab269 ![]() |
![]() ![]() | Sharma, A. B., Erasimus, H., Pinto, L., Caron, M.-C., Gopaul, D., Peterlini, T., Neumann, K., NAZAROV, P., FRITAH, S., KLINK, B., Herold-Mende, C. C., NICLOU, S. P., Pasero, P., Calsou, P., Masson, J.-Y., Britton, S., & Van Dyck, E. (27 September 2021). XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase. Nucleic Acids Research, 49 (17), 9906-9925. doi:10.1093/nar/gkab785 ![]() |
![]() ![]() | Kulkarni, A., Ferreira, T., Bretscher, C., Grewenig, A., El-Andaloussi, N., Bonifati, S., Marttila, T., PALISSOT, V., Hossain, J. A., AZUAJE, F., Miletic, H., Ystaas, L. A. R., GOLEBIEWSKA, A., NICLOU, S. P., Roeth, R., Niesler, B., Weiss, A., Brino, L., & MARCHINI, A. (22 June 2021). Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry. Nature Communications, 12 (1), 3834. doi:10.1038/s41467-021-24034-7 ![]() |
![]() ![]() | Oudin, A., Baus, V., Barthelemy, V., Fabian, C., KLEIN, E., Dieterle, M., Wantz, M., Hau, A.-C., DORDING, C., Bernard, A., MICHELUCCI, A., Yabo, Y. A., Kanli, G., Keunen, O., Bjerkvig, R., NICLOU, S. P., & GOLEBIEWSKA, A. (18 June 2021). Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors. STAR Protocols, 2 (2), 100534. doi:10.1016/j.xpro.2021.100534 ![]() |
![]() ![]() | NICLOU, S. P., & GOLEBIEWSKA, A. (April 2021). Turning strength into weakness: protein degradation and autophagy as therapeutic targets in glioblastoma? Neuro-Oncology, 23 (7), 1041–1043. doi:10.1093/neuonc/noab099 ![]() |
Fabian, C., Han, M., Bjerkvig, R., & NICLOU, S. P. (2021). Novel facets of glioma invasion. International Review of Cell and Molecular Biology, 360, 33-64. doi:10.1016/bs.ircmb.2020.08.001 ![]() |
![]() ![]() | Schuster, A., KLEIN, E., Neirinckx, V., Knudsen, A. M., Fabian, C., Hau, A.-C., Dieterle, M., Oudin, A., NAZAROV, P., GOLEBIEWSKA, A., Muller, A., Perez-Hernandez, D., Rodius, S., DITTMAR, G., Bjerkvig, R., Herold-Mende, C., KLINK, B., Kristensen, B. W., & NICLOU, S. P. (11 December 2020). AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications, 11 (1), 6366. doi:10.1038/s41467-020-20029-y ![]() |
![]() ![]() | White, K., Connor, K., Clerkin, J., Murphy, B. M., Salvucci, M., O'Farrell, A. C., REHM, M., O'Brien, D., Prehn, J. H. M., NICLOU, S. P., Lamfers, M. L. M., Verreault, M., Idbaih, A., Verhaak, R., GOLEBIEWSKA, A., & Byrne, A. T. (December 2020). New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Annals of Oncology, 31 (12), 1679-1692. doi:10.1016/j.annonc.2020.08.2336 ![]() |
![]() ![]() | GOLEBIEWSKA, A., Hau, A.-C., Oudin, A., Stieber, D., Yabo, Y. A., Baus, V., Barthelemy, V., Klein, E., Bougnaud, S., Keunen, O., Wantz, M., MICHELUCCI, A., Neirinckx, V., Muller, A., Kaoma, T., Nazarov, P. V., AZUAJE, F., De Falco, A., Flies, B., ... NICLOU, S. (2020). Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica. doi:10.1007/s00401-020-02226-7 ![]() |
![]() ![]() | FRITAH, S., Muller, A., Jiang, W., Mitra, R., Sarmini, M., Dieterle, M., GOLEBIEWSKA, A., Ye, T., Van Dyck, E., Herold-Mende, C., Zhao, Z., AZUAJE, F., & NICLOU, S. P. (10 September 2020). Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. Cancers, 12 (9). doi:10.3390/cancers12092583 ![]() |
![]() ![]() | GOLEBIEWSKA, A., Hau, A.-C., Oudin, A., Stieber, D., Yabo, Y. A., Baus, V., Barthelemy, V., Klein, E., Bougnaud, S., Keunen, O., Wantz, M., MICHELUCCI, A., Neirinckx, V., Muller, A., Kaoma, T., Nazarov, P. V., AZUAJE, F., De Falco, A., Flies, B., ... NICLOU, S. (2020). Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/43022. doi:10.1101/2020.04.24.057802 |
![]() ![]() | Keunen, O., & NICLOU, S. P. (2020). Is there a prominent role for MR spectroscopy in the clinical management of brain tumors? Neuro-Oncology. doi:10.1093/neuonc/noaa098 ![]() |
![]() ![]() | Le Rhun, E., Weller, M., NICLOU, S. P., Short, S., Piil, K., Boele, F., Rudà, R., Theodorou, M., Brandsma, D., van den Bent, M., & Dirven, L. (March 2020). Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. Neuro-Oncology Practice, 7 (2), 249-259. doi:10.1093/nop/npz053 ![]() |
![]() ![]() | Rodius, S., de Klein, N., Jeanty, C., Sánchez-Iranzo, H., Crespo, I., Ibberson, M., Xenarios, I., DITTMAR, G., Mercader, N., NICLOU, S. P., & AZUAJE, F. (19 February 2020). Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity. Scientific Reports, 10 (1), 2896. doi:10.1038/s41598-020-59894-4 ![]() |
![]() ![]() | FRITAH, S., & NICLOU, S. P. (2020). Dual blockade of STAT3 and EGFR: a key to unlock drug resistance in glioblastoma? Neuro-Oncology. doi:10.1093/neuonc/noaa039 ![]() |
![]() ![]() | Pires-Afonso, Y., NICLOU, S. P., & MICHELUCCI, A. (21 January 2020). Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma. International Journal of Molecular Sciences, 21 (3). doi:10.3390/ijms21030689 ![]() |
![]() ![]() | KLEIN, E., Hau, A.-C., Oudin, A., GOLEBIEWSKA, A., & NICLOU, S. P. (2020). Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. Frontiers in Oncology, 10, 604121. doi:10.3389/fonc.2020.604121 ![]() |
![]() ![]() | Biedermann, J., Preussler, M., Conde, M., Peitzsch, M., Richter, S., Wiedemuth, R., Abou-El-Ardat, K., Krüger, A., Meinhardt, M., Schackert, G., Leenders, W. P., Herold-Mende, C., NICLOU, S. P., Bjerkvig, R., Eisenhofer, G., Temme, A., Seifert, M., Kunz-Schughart, L. A., Schröck, E., & KLINK, B. (16 December 2019). Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 11 (12). doi:10.3390/cancers11122028 ![]() |
![]() ![]() | Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro, K. D., Alpar, D., Amin, S. B., Ashley, D. M., Bandopadhayay, P., Barnholtz-Sloan, J. S., Beroukhim, R., Bock, C., Brastianos, P. K., Brat, D. J., ... Verhaak, R. G. W. (Other coll.). (December 2019). Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 576 (7785), 112-120. doi:10.1038/s41586-019-1775-1 ![]() |
![]() ![]() | Zeiner, P. S., Preusse, C., GOLEBIEWSKA, A., Zinke, J., Iriondo, A., Muller, A., Kaoma, T., Filipski, K., Müller-Eschner, M., Bernatz, S., Blank, A.-E., Baumgarten, P., ILINA, E., Grote, A., Hansmann, M. L., Verhoff, M. A., Franz, K., Feuerhake, F., Steinbach, J. P., ... MITTELBRONN, M. (July 2019). Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. Brain Pathology, 29 (4), 513-529. doi:10.1111/bpa.12690 ![]() |
![]() ![]() | Reynders, Abboud, Baragli, Noman, Rogister, NICLOU, S. P., Heveker, JANJI, B., Hanson, SZPAKOWSKA, M., & Chevigné. (June 2019). The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells, 8 (6), 613. doi:10.3390/cells8060613 ![]() |
![]() ![]() | GOBIN, M., NAZAROV, P., Warta, R., Timmer, M., Reifenberger, G., Felsberg, J., Vallar, L., Chalmers, A. J., Herold-Mende, C. C., Goldbrunner, R., NICLOU, S. P., & Van Dyck, E. (15 March 2019). A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. Cancer Research, 79 (6), 1226-1238. doi:10.1158/0008-5472.CAN-18-2076 ![]() |
![]() ![]() | Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S., Brons, N. H. C., Leite, S., Sauvageot, N., Sarkisjan, D., Seyfrid, M., Fritah, S., Stieber, D., MICHELUCCI, A., Herold-Mende, C., Bjerkvig, R., Azuaje, F., SKUPIN, A., Deutsch, A., ... Hertel, F. (2019). Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature communications, 10 (1), 1787. doi:10.1038/s41467-019-09853-z ![]() |
![]() ![]() | Schuster, A., Erasimus, H. L. N., FRITAH, S., Nazarov, P., van Dyck, E., NICLOU, S. P., & GOLEBIEWSKA, A. (January 2019). RNAi/CRISPR Screens: from a Pool to a Valid Hit. Trends in Biotechnology, 37 (1), 38–55. doi:10.1016/j.tibtech.2018.08.002 ![]() |
![]() ![]() | PAVLOU, M. A., GRANDBARBE, L., Buckley, N., NICLOU, S., & MICHELUCCI, A. (2018). Transcriptional and epigenetic mechanisms underlying astrocyte identity. Progress in Neurobiology. doi:10.1016/j.pneurobio.2018.12.007 ![]() |
![]() ![]() | NICLOU, S. P. (09 October 2018). Revival of the VEGF ligand family? Neuro-Oncology, 20 (11), 1421-1422. doi:10.1093/neuonc/noy127 ![]() |
![]() ![]() | Obad, N., Espedal, H., Jirik, R., Sakariassen, P. O., Brekke Rygh, C., Lund-Johansen, M., Taxt, T., NICLOU, S. P., Bjerkvig, R., & Keunen, O. (October 2018). Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. Journal of Cerebral Blood Flow and Metabolism, 38 (10), 1741-1753. doi:10.1177/0271678X17714656 ![]() |
![]() ![]() | SOUSA, C., Golebiewska, A., Poovathingal, S. K., Kaoma, T., Pires-Afonso, Y., Martina, S., COOWAR, D., Azuaje, F., SKUPIN, A., BALLING, R., Biber, K., NICLOU, S., & MICHELUCCI, A. (2018). Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures. EMBO Reports. doi:10.15252/embr.201846171 ![]() |
![]() ![]() | Dudvarski Stanković, N., Bicker, F., Keller, S., Jones, D. T., Harter, P. N., Kienzle, A., Gillmann, C., Arnold, P., GOLEBIEWSKA, A., Keunen, O., Giese, A., von Deimling, A., Bäuerle, T., NICLOU, S. P., MITTELBRONN, M., Ye, W., Pfister, S. M., & Schmidt, M. H. (September 2018). EGFL7 enhances surface expression of integrin α(5)β(1) to promote angiogenesis in malignant brain tumors. EMBO Molecular Medicine, 10 (9). doi:10.15252/emmm.201708420 ![]() |
![]() ![]() | Mäder, L., Blank, A. E., Capper, D., Jansong, J., Baumgarten, P., Wirsik, N. M., Zachskorn, C., Ehlers, J., Seifert, M., KLINK, B., Liebner, S., NICLOU, S. P., Naumann, U., Harter, P. N., & MITTELBRONN, M. (08 May 2018). Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma. Oncotarget, 9 (35), 24041-24053. doi:10.18632/oncotarget.25275 ![]() |
![]() ![]() | MEISER, J., Schuster, A., Pietzke, M., Vande Voorde, J., Athineos, D., Oizel, K., Burgos-Barragan, G., Wit, N., Dhayade, S., Morton, J. P., Dornier, E., Sumpton, D., Mackay, G. M., Blyth, K., Patel, K. J., NICLOU, S. P., & Vazquez, A. (10 April 2018). Increased formate overflow is a hallmark of oxidative cancer. Nature Communications, 9 (1), 1368. doi:10.1038/s41467-018-03777-w ![]() |
![]() ![]() | Wierz, M., Pierson, S., Guyonnet, L., VIRY, E., Lequeux, A., Oudin, A., NICLOU, S. P., OLLERT, M., BERCHEM, G. J. M. J., JANJI, B., Guérin, C., PAGGETTI, J., & MOUSSAY, E. (05 April 2018). Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood, 131 (14), 1617-1621. doi:10.1182/blood-2017-06-792267 ![]() |
![]() ![]() | AZUAJE, F., Kaoma, T., Jeanty, C., NAZAROV, P., Muller, A., Kim, S.-Y., DITTMAR, G., GOLEBIEWSKA, A., & NICLOU, S. P. (2018). Hub genes in a pan-cancer co-expression network show potential for predicting drug responses. F1000Research, 7, 1906. doi:10.12688/f1000research.17149.2 ![]() |
![]() ![]() | Fack, F., Tardito, S., Hochart, G., Oudin, A., Zheng, L., FRITAH, S., GOLEBIEWSKA, A., Nazarov, P., Bernard, A., Hau, A.-C., Keunen, O., Leenders, W., Lund-Johansen, M., Stauber, J., Gottlieb, E., Bjerkvig, R., & NICLOU, S. P. (October 2017). Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways. EMBO Molecular Medicine, 9 (12), 1681–1695. doi:10.15252/emmm.201707729 ![]() |
![]() ![]() | Abdul Rahim, S. A., Dirkse, A., Oudin, A., Schuster, A., BOHLER, J., Barthelemy, V., Muller, A., Vallar, L., JANJI, B., GOLEBIEWSKA, A., & NICLOU, S. P. (05 September 2017). Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. British Journal of Cancer, 117 (6), 813-825. doi:10.1038/bjc.2017.263 ![]() |
![]() ![]() | Armento, A., ILINA, E., Kaoma, T., Muller, A., Vallar, L., NICLOU, S. P., Krüger, M. A., MITTELBRONN, M., & Naumann, U. (August 2017). Carboxypeptidase E transmits its anti-migratory function in glioma cells via transcriptional regulation of cell architecture and motility regulating factors. International Journal of Oncology, 51 (2), 702-714. doi:10.3892/ijo.2017.4051 ![]() |
![]() ![]() | Neirinckx, V., Hedman, H., & NICLOU, S. P. (August 2017). Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy. Biochimica et Biophysica Acta. Reviews on Cancer, 1868 (1), 109-116. doi:10.1016/j.bbcan.2017.02.007 ![]() |
Monaco, I., Camorani, S., Colecchia, D., Locatelli, E., Calandro, P., Oudin, A., NICLOU, S. P., Arra, C., Chiariello, M., Cerchia, L., & Comes Franchini, M. (25 May 2017). Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier. Journal of Medicinal Chemistry, 60 (10), 4510-4516. doi:10.1021/acs.jmedchem.7b00527 ![]() |
![]() ![]() | Talasila, K. M., Røsland, G. V., Hagland, H. R., Eskilsson, E., Flønes, I. H., FRITAH, S., AZUAJE, F., Atai, N., Harter, P. N., MITTELBRONN, M., Andersen, M., Joseph, J. V., Hossain, J. A., Vallar, L., Noorden, C. J. F. V., NICLOU, S. P., Thorsen, F., Tronstad, K. J., Tzoulis, C., ... Miletic, H. (01 March 2017). The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology, 19 (3), 383-393. doi:10.1093/neuonc/now175 ![]() |
Eskilsson, E., Rosland, G. V., Talasila, K. M., Knappskog, S., Keunen, O., Sottoriva, A., Foerster, S., Solecki, G., Taxt, T., Jirik, R., FRITAH, S., Harter, P. N., Välk, K., Al Hossain, J., Joseph, J. V., Jahedi, R., Saed, H. S., Piccirillo, S. G., Spiteri, I., ... Miletic, H. (December 2016). EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro-Oncology, 18 (12), 1644 - 1655. doi:10.1093/neuonc/now113 ![]() |
![]() ![]() | Bougnaud, S., GOLEBIEWSKA, A., Oudin, A., Keunen, O., Harter, P. N., Mäder, L., AZUAJE, F., FRITAH, S., Stieber, D., Kaoma, T., Vallar, L., Brons, N. H. C., Daubon, T., Miletic, H., Sundstrøm, T., Herold-Mende, C., MITTELBRONN, M., Bjerkvig, R., & NICLOU, S. P. (31 May 2016). Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget, 7 (22), 31955 - 31971. doi:10.18632/oncotarget.7454 ![]() |
![]() ![]() | Rodius, S., ANDROSOVA, G., Götz, L., Liechti, R., CRESPO, I., Merz, S., Nazarov, P., de Klein, N., Jeanty, C., González-Rosa, J., Muller, A., Bernardin, F., NICLOU, S., Vallar, L., Mercader, N., Ibberson, M., Xenarios, I., & Azuaje, F. (31 May 2016). Analysis of the dynamic co-expression network of heart regeneration in the zebrafish. Scientific Reports, 6. doi:10.1038/srep26822 ![]() |
![]() ![]() | Demeure, K., Fack, F., DURIEZ, E., Tiemann, K., Bernard, A., GOLEBIEWSKA, A., Bougnaud, S., Bjerkvig, R., Domon, B., & NICLOU, S. P. (February 2016). Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). Molecular and Cellular Proteomics, 15 (2), 481-92. doi:10.1074/mcp.M115.052423 ![]() |
Du Four, S., Maenhout, S. K., NICLOU, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016). Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. American Journal of Cancer Research, 6 (11), 2514-2531. ![]() |
Tardito, S., Oudin, A., Ahmed, S. U., Fack, F., Keunen, O., Zheng, L., Miletic, H., Sakariassen, P. Ø., Weinstock, A., Wagner, A., Lindsay, S. L., Hock, A. K., Barnett, S. C., Ruppin, E., Mørkve, S. H., Lund-Johansen, M., Chalmers, A. J., Bjerkvig, R., NICLOU, S. P., & Gottlieb, E. (December 2015). Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 17 (12), 1556 - 1568. doi:10.1038/ncb3272 ![]() |
Burtey, A., Wagner, M., Hodneland, E., Skaftnesmo, K. O., Schoelermann, J., Mondragon, I. R., Espedal, H., GOLEBIEWSKA, A., NICLOU, S. P., Bjerkvig, R., Kögel, T., & Gerdes, H.-H. (November 2015). Intercellular transfer of transferrin receptor by a contact-, Rab8-dependent mechanism involving tunneling nanotubes. FASEB Journal, 29 (11), 4695-712. doi:10.1096/fj.14-268615 ![]() |
![]() ![]() | NICLOU, S. P. (July 2015). Gauging heterogeneity in primary versus recurrent glioblastoma. Neuro-Oncology, 17 (7), 907-9. doi:10.1093/neuonc/nov078 ![]() |
![]() ![]() | Du Four, S., Maenhout, S. K., De Pierre, K., Renmans, D., NICLOU, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (April 2015). Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology, 4 (4), 998107. doi:10.1080/2162402X.2014.998107 ![]() |
![]() ![]() | AZUAJE, F., Tiemann, K., & NICLOU, S. P. (31 March 2015). Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma. Cell Communication and Signaling, 13, 23. doi:10.1186/s12964-015-0098-6 ![]() |
![]() ![]() | Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., Quek, K., Quinn, M. C. J., Robertson, A. J., Fadlullah, M. Z. H., Bruxner, T. J. C., Christ, A. N., Harliwong, I., Idrisoglu, S., Manning, S., Nourse, C., ... Hair, J. (Other coll.). (26 February 2015). Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518 (7540), 495-501. doi:10.1038/nature14169 ![]() |
![]() ![]() | Fack, F., Espedal, H., Keunen, O., GOLEBIEWSKA, A., Obad, N., Harter, P. N., MITTELBRONN, M., Bähr, O., Weyerbrock, A., Stuhr, L., Miletic, H., Sakariassen, P. Ø., Stieber, D., Rygh, C. B., Lund-Johansen, M., Zheng, L., Gottlieb, E., NICLOU, S. P., & Bjerkvig, R. (January 2015). Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathologica, 129 (1), 115-31. doi:10.1007/s00401-014-1352-5 ![]() |
![]() ![]() | Sanzey, M., Abdul Rahim, S. A., Oudin, A., Dirkse, A., Kaoma, T., Vallar, L., Herold-Mende, C., Bjerkvig, R., GOLEBIEWSKA, A., & NICLOU, S. P. (2015). Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma. PLoS ONE, 10 (5), 0123544. doi:10.1371/journal.pone.0123544 ![]() |
![]() ![]() | FRITAH, S., NICLOU, S. P., & AZUAJE, F. (November 2014). Databases for lncRNAs: a comparative evaluation of emerging tools. RNA, 20 (11), 1655-65. doi:10.1261/rna.044040.113 ![]() |
![]() ![]() | Bhujbal, S. V., de Haan, B., NICLOU, S. P., & de Vos, P. (31 October 2014). A novel multilayer immunoisolating encapsulation system overcoming protrusion of cells. Scientific Reports, 4, 6856. doi:10.1038/srep06856 ![]() |
![]() ![]() | Keunen, O., Taxt, T., Grüner, R., Lund-Johansen, M., Tonn, J.-C., Pavlin, T., Bjerkvig, R., NICLOU, S. P., & Thorsen, F. (30 September 2014). Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Advanced Drug Delivery Reviews, 76, 98-115. doi:10.1016/j.addr.2014.07.010 ![]() |
![]() ![]() | ANDROSOVA, G., Rodius, S., Nazarov, P., Muller, A., Bernardin, F., Jeanty, C., NICLOU, S., Vallar, L., & Azuaje, F. (08 September 2014). A comprehensive integrative analysis of the transcriptional network underlying the zebrafish heart regeneration [Poster presentation]. European Conference on Computational Biology, Strasbourg, France. |
![]() ![]() | Bhujbal, S. V., Paredes-Juarez, G. A., NICLOU, S. P., & de Vos, P. (September 2014). Factors influencing the mechanical stability of alginate beads applicable for immunoisolation of mammalian cells. Journal of the Mechanical Behavior of Biomedical Materials, 37, 196-208. doi:10.1016/j.jmbbm.2014.05.020 ![]() |
![]() ![]() | van Lith, S. A. M., Navis, A. C., Verrijp, K., NICLOU, S. P., Bjerkvig, R., Wesseling, P., Tops, B., Molenaar, R., van Noorden, C. J. F., & Leenders, W. P. J. (August 2014). Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers? Biochimica et Biophysica Acta, 1846 (1), 66-74. doi:10.1016/j.bbcan.2014.04.004 ![]() |
![]() ![]() | Torsvik, A., Stieber, D., Enger, P. Ø., GOLEBIEWSKA, A., Molven, A., Svendsen, A., Westermark, B., NICLOU, S. P., Olsen, T. K., Chekenya Enger, M., & Bjerkvig, R. (August 2014). U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Medicine, 3 (4), 812-24. doi:10.1002/cam4.219 ![]() |
![]() ![]() | Fathpour, P., Obad, N., Espedal, H., Stieber, D., Keunen, O., Sakariassen, P. Ø., NICLOU, S. P., & Bjerkvig, R. (May 2014). Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment? Neuro-Oncology, 16 (5), 754-6. doi:10.1093/neuonc/nou013 ![]() |
Bhujbal, S. V., de Vos, P., & NICLOU, S. P. (April 2014). Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors. Advanced Drug Delivery Reviews, 67-68, 142-53. doi:10.1016/j.addr.2014.01.010 ![]() |
![]() ![]() | Demeure, K., DURIEZ, E., Domon, B., & NICLOU, S. P. (2014). PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species. Frontiers in Genetics, 5, 305. doi:10.3389/fgene.2014.00305 ![]() |
![]() ![]() | Rajcevic, U., Knol, J. C., Piersma, S., Bougnaud, S., Fack, F., Sundlisaeter, E., Søndenaa, K., Myklebust, R., Pham, T. V., NICLOU, S. P., & Jiménez, C. R. (2014). Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. Proteome Science, 12, 39. doi:10.1186/1477-5956-12-39 ![]() |
![]() ![]() | Stieber, D., Golebiewska, A., Evers, L., Lenkiewicz, E., Brons, N. H. C., Nicot, N., Oudin, A., Bougnaud, S., HERTEL, F., Bjerkvig, R., Vallar, L., Barrett, M. T., & NICLOU, S. (2014). Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathologica, 127 (2), 203-19. doi:10.1007/s00401-013-1196-4 ![]() |
![]() ![]() | BAGINSKA, J., VIRY, E., BERCHEM, G. J. M. J., Poli, A., Noman, M. Z., van Moer, K., Medves, S., ZIMMER, J., Oudin, A., NICLOU, S. P., Bleackley, R. C., Goping, I. S., Chouaib, S., & JANJI, B. (22 October 2013). Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 110 (43), 17450-5. doi:10.1073/pnas.1304790110 ![]() |
![]() ![]() | Johansson, M., Oudin, A., Tiemann, K., Bernard, A., GOLEBIEWSKA, A., Keunen, O., Fack, F., Stieber, D., Wang, B., Hedman, H., & NICLOU, S. P. (September 2013). The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro-Oncology, 15 (9), 1200-11. doi:10.1093/neuonc/not054 ![]() |
Kofanova, O. A., Fack, F., NICLOU, S. P., & BETSOU, F. (June 2013). Combined effect of tissue stabilization and protein extraction methods on phosphoprotein analysis. Biopreservation and Biobanking, 11 (3), 161-5. doi:10.1089/bio.2013.0008 ![]() |
![]() ![]() | Daphu, I., Sundstrøm, T., Horn, S., Huszthy, P. C., NICLOU, S. P., Sakariassen, P. Ø., Immervoll, H., Miletic, H., Bjerkvig, R., & Thorsen, F. (June 2013). In vivo animal models for studying brain metastasis: value and limitations. Clinical and Experimental Metastasis, 30 (5), 695-710. doi:10.1007/s10585-013-9566-9 ![]() |
![]() ![]() | Navis, A. C., NICLOU, S. P., Fack, F., Stieber, D., van Lith, S., Verrijp, K., Wright, A., Stauber, J., Tops, B., Otte-Holler, I., Wevers, R. A., van Rooij, A., Pusch, S., von Deimling, A., Tigchelaar, W., van Noorden, C. J. F., Wesseling, P., & Leenders, W. P. J. (29 May 2013). Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. Acta Neuropathologica Communications, 1, 18. doi:10.1186/2051-5960-1-18 ![]() |
![]() ![]() | Talasila, K. M., Soentgerath, A., Euskirchen, P., Rosland, G. V., Wang, J., Huszthy, P. C., Prestegarden, L., Skaftnesmo, K. O., Sakariassen, P. Ø., Eskilsson, E., Stieber, D., Keunen, O., Brekka, N., Moen, I., Nigro, J. M., Vintermyr, O. K., Lund-Johansen, M., NICLOU, S. P., Mørk, S. J., ... Miletic, H. (May 2013). EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathologica, 125 (5), 683-98. doi:10.1007/s00401-013-1101-1 ![]() |
![]() ![]() | Talasila, K. M., Brekka, N., Mangseth, K., Stieber, D., Evensen, L., Rosland, G. V., Torsvik, A., Wagner, M., NICLOU, S. P., Mahesparan, R., Vintermyr, O. K., Bjerkvig, R., Nigro, J. M., & Miletic, H. (2013). Tumor versus stromal cells in culture--survival of the fittest? PLoS ONE, 8 (12), 81183. doi:10.1371/journal.pone.0081183 ![]() |
![]() ![]() | Petersen, K., Rajcevic, U., Abdul Rahim, S. A., Jonassen, I., Kalland, K.-H., Jimenez, C. R., Bjerkvig, R., & NICLOU, S. P. (2013). Gene set based integrated data analysis reveals phenotypic differences in a brain cancer model. PLoS ONE, 8 (7), 68288. doi:10.1371/journal.pone.0068288 ![]() |
![]() ![]() | Golebiewska, A., Bougnaud, S., Stieber, D., Brons, N. H. C., Vallar, L., HERTEL, F., Klink, B., Schrock, E., Bjerkvig, R., & NICLOU, S. (2013). Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain: a Journal of Neurology, 136 (Pt 5), 1462-75. doi:10.1093/brain/awt025 ![]() |
B, K., H, M., D, S., PC, H., JAC, V., J, B., J, W., M, S., PØ, S., T, S., A, T., M, A., JM, N., & NICLOU, S. P. (2013). Correction: A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLoS ONE. doi:10.1371/annotation/72a01ce5-b0ad-4cbd-ac77-0a81347a3940 ![]() |
B, K., H, M., D, S., PC, H., JA, C., J, B., J, W., M, S., PØ, S., T, S., A, T., M, A., JM, N., & NICLOU, S. P. (2013). A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS ONE. doi:10.1371/journal.pone.0059773 ![]() |
![]() ![]() | Huszthy, P. C., Daphu, I., NICLOU, S. P., Stieber, D., Nigro, J. M., Sakariassen, P. Ø., Miletic, H., Thorsen, F., & Bjerkvig, R. (August 2012). In vivo models of primary brain tumors: pitfalls and perspectives. Neuro-Oncology, 14 (8), 979-93. doi:10.1093/neuonc/nos135 ![]() |
![]() ![]() | Viel, T., Talasila, K. M., Monfared, P., Wang, J., Jikeli, J. F., Waerzeggers, Y., Neumaier, B., Backes, H., Brekka, N., Thorsen, F., Stieber, D., NICLOU, S. P., Winkeler, A., Tavitian, B., Hoehn, M., Bjerkvig, R., Miletic, H., & Jacobs, A. H. (July 2012). Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI. Journal of Nuclear Medicine, 53 (7), 1135-45. doi:10.2967/jnumed.111.101659 ![]() |
Stieber, D., Abdul Rahim, S. A., & NICLOU, S. P. (October 2011). Novel ways to target brain tumour metabolism. Expert Opinion on Therapeutic Targets, 15 (10), 1227-39. doi:10.1517/14728222.2011.588211 ![]() |
![]() ![]() | Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., Thorsen, F., Taxt, T., Bartos, M., Jirik, R., Miletic, H., Wang, J., Stieber, D., Stuhr, L., Moen, I., Rygh, C. B., Bjerkvig, R., & NICLOU, S. P. (01 March 2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 108 (9), 3749-54. doi:10.1073/pnas.1014480108 ![]() |
![]() ![]() | GOLEBIEWSKA, A., Brons, N. H. C., Bjerkvig, R., & NICLOU, S. P. (04 February 2011). Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell, 8 (2), 136-47. doi:10.1016/j.stem.2011.01.007 ![]() |
![]() ![]() | Goplen, D., Bougnaud, S., Rajcevic, U., Bøe, S. O., Skaftnesmo, K. O., Voges, J., Enger, P. Ø., Wang, J., Tysnes, B. B., Laerum, O. D., NICLOU, S. P., & Bjerkvig, R. (October 2010). αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. American Journal of Pathology, 177 (4), 1618-28. doi:10.2353/ajpath.2010.090063 ![]() |
![]() ![]() | NICLOU, S. P., Fack, F., & Rajcevic, U. (10 September 2010). Glioma proteomics: status and perspectives. Journal of Proteomics, 73 (10), 1823-38. doi:10.1016/j.jprot.2010.03.007 ![]() |
![]() ![]() | Ehlert, E. M., Eggers, R., NICLOU, S. P., & Verhaagen, J. (18 February 2010). Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neuroscience, 11, 20. doi:10.1186/1471-2202-11-20 ![]() |
![]() ![]() | Rajcevic, U., Petersen, K., Knol, J. C., Loos, M., Bougnaud, S., Klychnikov, O., Li, K. W., Pham, T. V., Wang, J., Miletic, H., Peng, Z., Bjerkvig, R., Jimenez, C. R., & NICLOU, S. P. (November 2009). iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Molecular and Cellular Proteomics, 8 (11), 2595-612. doi:10.1074/mcp.M900124-MCP200 ![]() |
![]() ![]() | Bjerkvig, R., Johansson, M., Miletic, H., & NICLOU, S. P. (October 2009). Cancer stem cells and angiogenesis. Seminars in Cancer Biology, 19 (5), 279-84. doi:10.1016/j.semcancer.2009.09.001 ![]() |
Miletic, H., NICLOU, S. P., Johansson, M., & Bjerkvig, R. (April 2009). Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opinion on Therapeutic Targets, 13 (4), 455-68. doi:10.1517/14728220902806444 ![]() |
![]() ![]() | Rajcevic, U., NICLOU, S. P., & Jimenez, C. R. (01 January 2009). Proteomics strategies for target identification and biomarker discovery in cancer. doi:10.2741/3452 ![]() |
![]() ![]() | Johansson, U., Rasmusson, I., NICLOU, S. P., Forslund, N., Gustavsson, L., Nilsson, B., Korsgren, O., & Magnusson, P. U. (September 2008). Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes, 57 (9), 2393-401. doi:10.2337/db07-0981 ![]() |
![]() ![]() | NICLOU, S. P., Danzeisen, C., Eikesdal, H. P., Wiig, H., Brons, N. H. C., Poli, A. M. F., Svendsen, A., Torsvik, A., Enger, P. Ø., Terzis, J. A., & Bjerkvig, R. (September 2008). A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB Journal, 22 (9), 3120-8. doi:10.1096/fj.08-109611 ![]() |
Terzis, A. J. A., NICLOU, S. P., Rajcevic, U., Danzeisen, C., & Bjerkvig, R. (August 2006). Cell therapies for glioblastoma. Expert Opinion on Biological Therapy, 6 (8), 739-49. doi:10.1517/14712598.6.8.739 ![]() |
F, D., T, V., FJ, S., LA, W., PR, B., van Muiswinkel FL, J, V., & NICLOU, S. P. (2006). The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Molecular and Cellular Neuroscience. doi:10.1016/j.mcn.2006.03.002 ![]() |
HH, M., S, C., NICLOU, S. P., RS, N., A, W., MG, W., KE, R., MG, S., & A, C. (2006). A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. Journal of Neuroscience. doi:10.1523/jneurosci.0702-05.2006 ![]() |
![]() ![]() | Hu, Y., Leaver, S. G., Plant, G. W., Hendriks, W. T. J., NICLOU, S. P., Verhaagen, J., Harvey, A. R., & Cui, Q. (June 2005). Lentiviral-mediated transfer of CNTF to schwann cells within reconstructed peripheral nerve grafts enhances adult retinal ganglion cell survival and axonal regeneration. Molecular Therapy, 11 (6), 906-15. doi:10.1016/j.ymthe.2005.01.016 ![]() |
Sinnreich, M., Meins, M., NICLOU, S. P., Suidan, H. S., & Monard, D. (March 2004). Prothrombin overexpressed in post-natal neurones requires blood factors for activation in the mouse brain. Journal of Neurochemistry, 88 (6), 1380-8. doi:10.1046/j.1471-4159.2003.02268.x ![]() |
![]() ![]() | Ahmed, B. Y., Chakravarthy, S., Eggers, R., Hermens, W. T. J. M. C., Zhang, J. Y., NICLOU, S. P., Levelt, C., Sablitzky, F., Anderson, P. N., Lieberman, A. R., & Verhaagen, J. (30 January 2004). Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neuroscience, 5, 4. doi:10.1186/1471-2202-5-4 ![]() |
![]() ![]() | NICLOU, S. P., Franssen, E. H. P., Ehlert, E. M. E., Taniguchi, M., & Verhaagen, J. (December 2003). Meningeal cell-derived semaphorin 3A inhibits neurite outgrowth. Molecular and Cellular Neuroscience, 24 (4), 902-12. doi:10.1016/s1044-7431(03)00243-4 ![]() |
![]() ![]() | Shearer, M. C., NICLOU, S. P., Brown, D., Asher, R. A., Holtmaat, A. J. G. D., Levine, J. M., Verhaagen, J., & Fawcett, J. W. (December 2003). The astrocyte/meningeal cell interface is a barrier to neurite outgrowth which can be overcome by manipulation of inhibitory molecules or axonal signalling pathways. Molecular and Cellular Neuroscience, 24 (4), 913-25. doi:10.1016/j.mcn.2003.09.004 ![]() |
![]() ![]() | Ruitenberg, M. J., Plant, G. W., Christensen, C. L., Blits, B., NICLOU, S. P., Harvey, A. R., Boer, G. J., & Verhaagen, J. (January 2002). Viral vector-mediated gene expression in olfactory ensheathing glia implants in the lesioned rat spinal cord. Gene Therapy, 9 (2), 135-46. doi:10.1038/sj.gt.3301626 ![]() |
![]() ![]() | NICLOU, S. P., Jia, L., & Raper, J. A. (01 July 2000). Slit2 is a repellent for retinal ganglion cell axons. Journal of Neuroscience, 20 (13), 4962-74. doi:10.1523/JNEUROSCI.20-13-04962.2000 ![]() |
NICLOU, S. P., Suidan, H. S., Pavlik, A., Vejsada, R., & Monard, D. (May 1998). Changes in the expression of protease-activated receptor 1 and protease nexin-1 mRNA during rat nervous system development and after nerve lesion. European Journal of Neuroscience, 10 (5), 1590-607. doi:10.1046/j.1460-9568.1998.00183.x ![]() |
![]() ![]() | Suidan, H. S., NICLOU, S. P., Dreessen, J., Beltraminelli, N., & Monard, D. (15 November 1996). The thrombin receptor is present in myoblasts and its expression is repressed upon fusion. Journal of Biological Chemistry, 271 (46), 29162-9. doi:10.1074/jbc.271.46.29162 ![]() |
Suidan, H. S., Clemetson, K. J., Brown-Luedi, M., NICLOU, S. P., Clemetson, J. M., Tschopp, J., & Monard, D. (01 May 1996). The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin. Biochemical Journal, 315 ( Pt 3) (Pt 3), 939-45. doi:10.1042/bj3150939 ![]() |
Suidan, H. S., NICLOU, S. P., & Monard, D. (1996). The thrombin receptor in the nervous system. Seminars in Thrombosis and Hemostasis, 22 (2), 125-33. doi:10.1055/s-2007-998999 ![]() |